Body

New research presented at this year's Euroanaesthesia congress in Copenhagen, Denmark shows that in patients undergoing a coronary artery bypass graft (CABG) surgery, taking aspirin before and after surgery is associated with an 18% to 34% reduced mortality risk after 4 years. The study is by Professor Jianzhong Sun, Director of Clinical Outcomes Research at the Department of Anesthesiology, Thomas Jefferson University and Hospitals, Philadelphia, USA, and colleagues.

New research presented at this year's Euroanaesthesia congress in Copenhagen, Denmark shows that hypnosedation is a valuable alternative to conventional general anaesthesia.

MAYWOOD, IL - A 21-gene test performed on tumors could enable most patients with the most common type of early breast cancer to safely forgo chemotherapy, according to a landmark study published in the New England Journal of Medicine.

The drug crizotinib has activity against a number of genetic targets relevant to non-small cell lung cancer, already earning FDA-approval against ALK- and ROS1-positive lung cancers. Now updated phase 1 clinical trial results presented at the American Association for Clinical Oncology (ASCO) Annual Meeting 2018 show a 40 percent response rate and 6.7-month median progression-free survival from crizotinib in highly MET-amplified non-small cell lung cancer, as well.

HOUSTON ? Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease.

CHICAGO - A test that analyzes free-floating DNA in the blood may be able to detect early-stage lung cancer, a preliminary report from the ongoing Circulating Cell-Free Genome Atlas (CCGA) study suggests.

The findings, from one of the first studies to explore whether sequencing blood-borne DNA is a feasible approach to the early cancer detection, will be featured in a press briefing today and presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

CHICAGO - Matching targeted therapies to tumor-specific gene mutations across tumor types improved progression-free survival (PFS) and overall survival (OS) in patients with advanced disease relative to those receiving non-matched treatment (NMT), according to research from The University of Texas MD Anderson Cancer Center. The researchers also found that receiving matched targeted therapy (MTT) was an independent factor for predicting longer OS.

Early phase clinical trial results presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 of 258 patients with IDH1+ acute myeloid leukemia (AML) treated with the IDH1 inhibitor ivosidenib show an overall response rate of 41.9 percent, with median progression free survival of 8.2 months. Twenty-four percent of patients achieved a complete response.

Bottom Line: Population aging and growth largely fueled an increase in cancer cases between 2006 and 2016, and large disparities continue to exist between countries in cancer incidence, deaths and the disease's associated disability.

Why The Research Is Interesting: An assessment of the impact of cancer over time can help to frame policy discussions, resource allocation and research focus.

What and When: Cancer incidence, mortality and related disability evaluated for 195 countries and territories with a focus on changes in the last decade (2006-2016).

BOSTON -- Researchers from Hebrew SeniorLife's Institute for Aging Research, Boston University, Beth Israel Deaconess Medical Center, and University of Calgary have found evidence that weight loss can result in worsening bone density, bone architecture and bone strength. The results were published in the Journal of Bone and Mineral Research.